pitavastatin / Generic mfg. - LARVOL DELTA

A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors. (PubMed, Mol Pharm) - "Notably, PIT-SAL additionally exhibited antitumor potential by effectively reducing tumoral cholesterol accumulation while enhancing T-cell infiltration. Collectively, our preliminary findings highlight the great translational potential of PIT-SAL as a targeted therapy for both AS and tumors, offering a potential breakthrough in managing these interconnected diseases."

Journal • Atherosclerosis • Cardiovascular • Oncology

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. (PubMed, Clin Transl Sci) - "Cohort 3 received an oral solution containing microdoses of dabigatran (P-gp), pitavastatin (OATP1B1), rosuvastatin (BCRP, OATP, and P-gp), atorvastatin (BCRP, OATP, P-gp, and CYP3A4), and midazolam...Steady-state ecopipam administration increased dextromethorphan exposure (> 100-fold); decreased the AUCinf of midazolam, omeprazole, and dabigatran by 44.2%, 44.1%, and 37.9%, respectively; and decreased unconjugated bilirubin (UGT1A1) by 19.5%...There were no changes in caffeine, bupropion, or pitavastatin exposure. Ecopipam is a strong inhibitor of CYP2D6 and weak inducer of CYP3A4, CYP2C19, P-gp, and UGT1A1. Ecopipam did not inhibit CYP3A4, CYP2C19, CYP2B6, CYP1A2, UGT1A1, P-gp, or OATP1B1 and did not induce OATP1B1 or CYP2B6."

Journal • PK/PD data • Movement Disorders • Tourette Syndrome • CYP1A2 • CYP2C19 • CYP3A4 • UGT1A1

Chemotherapy plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer: An Exploratory Phase I Trial (ChiCTR) - P=N/A | N=22 | Not yet recruiting | Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Economic implications of the different statin prescribing patterns in Central Portugal: a longitudinal analysis. (PubMed, J Pharm Policy Pract) - "These discrepancies were associated with the percentage of pitavastatin in DDD (F = 4.604; p = 0.005), and the percentage of statins monotherapy in DDD (F = 5.201; p = 0.003)...Differences in prescribing patterns resulted in very different proportions of patients treated and expenses associated with the consumption of these lipid-lowering agents. Further analysis should be carried out to understand the financial implications of prescribing new (patent-protected) medicines in Portugal."

Journal

CPPGPTCLC: Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: Chang Chen

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

PROBUCOL HALVES ALL-CAUSE DEMENTIA RISK: EVIDENCE FROM A NATIONWIDE COHORT (ADPD 2026) - P2 | "Protective associations were consistent across individual statins, most pronounced versus pravastatin (aOR = 0.31, 95% CI: 0.24–0.38) and pitavastatin (aOR = 0.30, 95% CI: 0.24–0.38). Conclusions Probucol use was associated with significant lower odds of dementia, with robust effects across statin comparators. These findings highlight the translational potential of targeting peripheral amyloid–capillary interactions. Confirmation in the ongoing Probucol in Alzheimer's Study (ACTRN12621000726853) could provide a compelling rationale for scalable and cost-effective adoption of probucol in dementia prevention and treatment."

Alzheimer's Disease • CNS Disorders • Dementia • Inflammation

Impact of pitavastatin on carotid plaque regression in patients with hypercholesterolemia. (PubMed, Ann Vasc Surg) - "The pitavastatin-based lipid-lowering treatment resulted in statistically significant regression of carotid atherosclerotic plaques. More research is needed to determine the effects of the observed changes on clinical outcomes."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®. (PubMed, Ther Innov Regul Sci) - "A new user cohort design was employed in which patients prescribed one of six statins (atorvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, or rosuvastatin) in Japan between January 1, 2014 and March 31, 2022 were identified in the MID-NET® database. Results suggest that risks of liver dysfunction by generic statins are similar to those for brand drugs, facilitating our understanding about the safety of generic drugs. The aHR for atorvastatin was inconsistent between the primary and additional analyses, which suggests that the observed increased risk of generic atorvastatin may be affected by other factors and does not necessarily indicate a different safety profile between generic and brand drugs."

Journal • Hepatology • Liver Failure

Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients (SABCS 2025) - "Background: Ribociclib is approved for the treatment of HR+/HER2- advanced or metastatic breast cancer (ABC) in combination with an aromatase inhibitor or fulvestrant, and more recently, for the adjuvant treatment of HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence, with the starting dose of 600 mg in ABC and 400mg in EBC...The effect of ribociclib on rosuvastatin, pravastatin, pitavastatin, and fluvastatin is considered minor with no clinical relevance, since these statins are not sensitive CYP3A4 substrates...No clinically relevant DDI is expected for commonly used antidepressants/antipsychotics, such as citalopram, escitalopram, fluoxetine, mirtazapine, sertraline, trazodone, venlafaxine, aripiprazole, olanzapine and cariprazine, when co-administered with ribociclib 400 mg or 600 mg... No clinically relevant DDI with ribocicilib is anticipated for commonly used statins or antidepressants/antipsychotics, except simvastatin, lovastatin,..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVE. (PubMed, J Am Heart Assoc) - "Among PWH in REPRIEVE, electrocardiographic abnormalities were common, but major electrocardiographic abnormalities were rare. Though major abnormalities were associated with increased hazard of MACEs, routine electrocardiographic screening is unlikely to improve the prediction of future cardiovascular events in this primary prevention population with low to moderate cardiovascular risk."

Journal • Atherosclerosis • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

OPTIMAR: Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Kirby Institute | Recruiting ➔ Active, not recruiting

Enrollment closed • Congestive Heart Failure • Human Immunodeficiency Virus • Infectious Disease

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate. (PubMed, bioRxiv) - "Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in TP53 -mutant AML. The pro-apoptotic actions of pitavastatin depend on depletion of geranylgeranyl pyrophosphate (GGPP) and can be recapitulated by inhibiting GGPP synthase or geranylgeranyltransferase-1 enzymes. These results provide a mechanistic rationale for adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • FLT3 • MCL1 • TP53

Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial. (PubMed, JACC Cardiovasc Imaging) - P3 | "PCAT density increases over time in PWH, but pitavastatin mitigates this in those with high coronary artery disease burden. PCAT density is associated with vulnerable plaque morphology and all-cause mortality, supporting its potential as a prognostic imaging biomarker in PWH. (Randomized Trial to Prevent Vascular Events in HIV [REPRIEVE]; NCT02344290)."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Human Immunodeficiency Virus • Infectious Disease

Identification of osteoarthritis-related genes and potential drugs based on single cell RNA-seq data. (PubMed, Mol Med) - "The RT-qPCR results of zebrafish verified that Pitavastatin inhibited the expression of HMGCR, while Cabazitaxel inhibited the expression of TUBB1. Our study suggested that Pitavastatin has therapeutic effects on OA, while Cabazitaxel increases the risk of OA."

Journal • Cardiovascular • Genito-urinary Cancer • Immunology • Oncology • Osteoarthritis • Pain • Prostate Cancer • Rheumatology • Solid Tumor • BIRC3 • CCL20 • CXCL8 • ICAM1 • MMP3 • TUBB1

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Pitavastatin Potentiates Mitochondrial Dysfunction and Venetoclax Cytotoxicity in Acute Myeloid Leukemia Cells (ASH 2024) - P1 | "Notably, PIT sensitizes AML cells to venetoclax by upregulating PUMA via a p53-independent mechanism and by reducing mitochondrial fitness. These results demonstrate that targeting the mevalonate pathway with PIT in combination with venetoclax might be effective to overcome resistance, increase survival and improve clinical outcome."

IO biomarker • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • BBC3 • TSC22D3

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL (ASH 2023) - P1 | "AML patients were eligible if receiving induction therapy with azacitidine (AZA) and VEN per standard of care. CLL/SLL patients could receive either VEN with obinutuzumab (O) or rituximab...In 2 patient peripheral blood samples analyzed, the % blasts (for an AML sample) and % CD5+ B-cells (for a CLL sample) were reduced 24 hours after PIT dosing compared to prior to any treatment and before PIT/after VEN ramp-up. Based on the tolerability of PIT and encouraging clinical outcomes, a phase 2 study is being planned to better assess the efficacy of adding PIT to VEN-based therapies in AML and CLL/SLL."

IO biomarker • P1 data • Acute Myelogenous Leukemia • Anemia • Chronic Lymphocytic Leukemia • Dyslipidemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Metabolic Disorders • Musculoskeletal Pain • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pancreatitis • Small Lymphocytic Lymphoma • Thrombocytopenia • CD5

A Case of Statin-Associated Muscle Symptoms (SAMS) Due to Drug-Drug Interaction between Statin and Pazopanib (PubMed, Hinyokika Kiyo) - "However, axitinib therapy was discontinued due to hand-foot syndrome and nivolumab therapy was initiated in 2021. Previous reports have indicated that tyrosine kinase inhibitors, such as pazopanib, can inactivate OATP1B1, leading to an increase in the plasma concentration of statins. In the present case, myositis was considered to have resulted from a drug-drug interaction between pitavastatin and pazopanib."

Journal • Dermatology • Fatigue • Genito-urinary Cancer • Hepatology • Immunology • Infectious Disease • Liver Failure • Myositis • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants. (PubMed, Clin Transl Sci) - "As an object of organic anion transporting polypeptide (OATP) 1B1/1B3 and P-glycoprotein inhibition (cyclosporine A), remdesivir and GS-704277 exposures increased 2-fold and 3-fold, respectively, while GS-441524 was unchanged...As an object of strong cytochrome P450 (CYP) 3A induction (carbamazepine), exposure changes of remdesivir and its metabolites were not clinically significant. As an inhibitor, single-dose remdesivir did not impact pitavastatin (OATP1B1/1B3 substrate) exposures but increased midazolam (CYP3A substrate) Cmax (29%) to a greater extent than AUCinf (20%)...As an inducer with midazolam (CYP3A substrate), multiple-dose remdesivir did not decrease exposures but rather transiently increased midazolam exposures to a similar degree as observed in the inhibition study. Remdesivir may be coadministered with other medications without restrictions."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial. (PubMed, AIDS) - P3 | "Among this cohort of ART-treated PWH, baseline cardiometabolic risk factors were associated with worse self-reported physical HRQoL, with no apparent effect of statin therapy."

HEOR • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Human Immunodeficiency Virus • Infectious Disease

Consensus Virtual Screening and Ex Vivo Evaluation of Novel JAK2/STAT1,3 Inhibitors. (PubMed, ACS Omega) - "In the ex vivo evaluations, pitavastatin (0.5004 μM), eltrombopag (0.2548 μM), flavoxate (0.1536 μM), and empagliflozin (0.2548 μM) affected the phosphorylation of downstream STAT1 and STAT3 signaling molecules, similarly to tofacitinib citrate (TOF) (1.2 nM ). These results encourage further in-depth preclinical experiments aimed at exploring the additional effects of the JAK2-STAT1/3 signaling pathway."

Journal • Preclinical • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • IL6 • JAK2 • STAT1

Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial. (PubMed, Arterioscler Thromb Vasc Biol) - P3 | "Adjustments for pitavastatin treatment did not attenuate this association...However, a large CHIP was associated with increased risk of myocardial infarction and revascularization. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02344290."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Myocardial Infarction • Peripheral Arterial Disease • CD4

PITAVASTATIN/EZETIMIBE VS. HIGH-DOSE STATINS IN PRE-DIABETES: HYPERLIPIDEMIA CONTROL AND STROKE PREVENTION (WSC 2025) - " We reviewed clinical trial data and meta-analyses comparing pitavastatin/ezetimibe combination therapy with high-dose statins (e.g., atorvastatin 40-80 mg, rosuvastatin 20-40 mg) in patients with hyperlipidemia and impaired glucose metabolism. In pre-DM patients, pitavastatin/ezetimibe combination therapy may provide effective hyperlipidemia control and stroke prevention with a reduced T2DM risk compared to high-dose statins. These findings support personalized lipid-lowering strategies to optimize cerebrovascular outcomes in this high-risk population. Further prospective trials are warranted."

Cardiovascular • Dyslipidemia • Hematological Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer. (PubMed, Exp Hematol Oncol) - "PITA's inhibition of Mcl-1 represents a novel mechanism to address treatment-refractory metastatic TNBC. Further assessment of PITA's therapeutic potential is warranted."

Journal • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Triple Negative Breast Cancer • ALDH1A1 • BCL2

Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study. (PubMed, PLoS One) - "Survival outcomes were additionally examined across different statin types, including atorvastatin, rosuvastatin, simvastatin and pitavastatin, using stratified Kaplan-Meier analysis. Stratified survival curves showed comparable trends among the different statin types. These findings suggest a potential class-wide survival benefit of statin therapy in the ICU setting for HF patients and highlight the need for further studies to determine whether specific statin selection offers additional clinical advantages."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure